cancer drugs

Latest Headlines

Latest Headlines

UPDATE: Influential cancer group releases first batch of affordability info on cancer meds

The National Comprehensive Cancer Network unveiled its first set of "evidence blocks" that include cost information on oncology drugs.

Influential cancer group to add drug-cost data to its treatment advice

When a U.S. cancer patient is prescribed drugs by their doctors now, the financial consequences play out over the course of treatment.

Cancer group fuels drug price debate with data comparing cost and effectiveness

Under the current model in the U.S. a cancer patient is prescribed drugs by their doctors and the financial consequences then play out over the course of the treatment. But in the midst of a growing national debate over drug prices, a coalition of cancer groups will provide patients with info ranking costs and effectiveness of different treatments so they can make decisions on what they are willing to pay for their own treatment.

BMJ points up 'wide variations' in quality of data for new FDA indications

One of pharma's key strategies for growing a drug's sales is expanding into bigger groups of patients. Thing is, the BMJ contends, those follow-up studies are often less stringent than they should be.

Report: Cancer drug spending fuels large increases in Medicare discount drug program

Cancer drug spending has drawn the ire of payers, patients and doctors unhappy with skyrocketing costs for the meds. Now another voice is joining the chorus of naysayers, as a new report from a cancer community nonprofit organization found that a government discount drug program is profiting off the rising costs of cancer meds.

Payers think they can squeeze prices on cancer immunotherapies? Not so fast, analyst says

Looking for an antidote to all the payer chest-thumping about cancer drug prices? Here's some news to suit pharma, at least when it comes to cancer immunotherapies. One big distinction in health insurance--between medicines patients take at home and those they receive at doctors' offices--should put a crimp in payers' efforts to squeeze out discounts on PD-1 and PD-L1 therapies.

UPDATED: Merck cancer drugs and Sanofi, Amgen cardio meds have formularies on high alert

U.S. drug payers have been able to beat back high prices for some COPD and diabetes drugs, much to the chagrin of GlaxoSmithKline and Sanofi. But several new categories promise to break out in a big way, and we are not talking just about hepatitis C drugs.

ASCO proposes cancer drug scorecard, with some scary examples for Big Pharma

​The American Society of Clinical Oncology promised a rating scale for cancer drugs--and now, it has delivered. Let the blowback begin.

UPDATED: Blockbuster-to-be cancer meds outclass other big launches--except Sovaldi and statins

No question, immuno-oncology drugs are the hottest tickets in cancer--and among the hottest across the board. But PD-1/PD-L1 treatments, including Merck & Co.'s Keytruda and Bristol-Myers Squibb's Opdivo, aren't the first to bear big sales expectations. How do immuno-oncology forecasts stack up against other notable drug launches?

Top oncologist joins chorus of pricing critics in high-profile ASCO speech

Pharma types are getting a wee bit defensive about critics' attacks on cancer drug prices, if response to  FiercePharma 's recent coverage is any indication. But the criticism just keeps on coming, even as drugmakers work with payers behind the scenes on mutually acceptable pricing deals.